We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Meda Expands Axorid Collaboration
News

Meda Expands Axorid Collaboration

Meda Expands Axorid Collaboration
News

Meda Expands Axorid Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Meda Expands Axorid Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe.

Axorid consists of the well-known and broadly used substances; ketoprofen, a NSAID (Non Sterodial Anti-Inflammatory Drug) for the treatment of rheumatic disorders, and omeprazole, an acid reducing proton pump inhibitor (PPI). Axorid can prevent gastrointestinal side effects from use of NSAIDs. Axorid’s once-daily administration can also increase patient compliance.
Advertisement